This suggests that passive immunization with tau antibodies is often a feasible therapeutic focus on and that the CSF degree of p-tau262/356 or with the microtubule binding domain (MTBD) can function a practical biomarker of tau pathology to observe tau therapeutics in medical trials. Critical re